Recruiting studies: Squamous Cell Carcinoma Of The Hypopharynx

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Stud
Phase 3 · 9 location(s) · Radboud University Medical Center · NCT05333523 Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patient
Phase 2 · 153 location(s) · NRG Oncology · NCT06532279 Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
Phase 3 · 8 location(s) · Centre Leon Berard · NCT06706401 A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Ca
Phase 3 · 205 location(s) · Merus B.V. · NCT06525220 The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma
NA · 3 location(s) · Eye & ENT Hospital of Fudan University · NCT05494190 BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196 Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel
Phase N/A · 1 location(s) · University of Erlangen-Nürnberg Medical School · NCT06947668 Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Phase 1 · 18 location(s) · National Cancer Institute (NCI) · NCT05172245 Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer
Phase 2 · 3 location(s) · Olgun Elicin · NCT07058805 Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Phase 2 · 100 location(s) · National Cancer Institute (NCI) · NCT07195734 Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07665190 Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Can
Phase N/A · 1 location(s) · University of Colorado, Denver · NCT00900419 De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
Phase 2/Phase 3 · 1 location(s) · University of Erlangen-Nürnberg Medical School · NCT06030440 A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07063212 Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
Phase N/A · 4 location(s) · Vanderbilt University Medical Center · NCT00898638 Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT07156227 Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Ch
Phase 2 · 178 location(s) · National Cancer Institute (NCI) · NCT04671667 Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spre
Phase 3 · 192 location(s) · National Cancer Institute (NCI) · NCT06589804 Window of Opportunity in Preserving Laryngeal Function Trial
Phase 2 · 1 location(s) · Matthew Spector · NCT07423078 5-Fluorouracil Response and Optimization STudy (The FROST Trial)
Phase 2 · 1 location(s) · Washington University School of Medicine · NCT07419464 Thermoradiotherapy for Locally Advanced Head and Neck Cancer Patients
Phase 1 · 1 location(s) · Erasmus Medical Center · NCT06761937 European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]
Phase 2 · 9 location(s) · University of Leipzig · NCT06137378 TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous
Phase 1 · 2 location(s) · Emory University · NCT06868433 Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radi
NA · 1 location(s) · Emory University · NCT06662058 Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
Phase N/A · 2 location(s) · AIO-Studien-gGmbH · NCT06380686 VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Phase 1/Phase 2 · 15 location(s) · VM Oncology, LLC · NCT03556228 Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone i
Phase 2 · 6 location(s) · National Cancer Institute (NCI) · NCT06980038 Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Phase 2 · 2 location(s) · Emory University · NCT06636734 Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascula
EARLY_Phase 1 · 1 location(s) · Emory University · NCT06914999 Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
NA · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT01473784

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.